22 Eli Lilly and the Tirzepatide Portfolio: Manufacturing as a Moat While Novo Nordisk has focused heavily on the longevity of a single molecule, Eli Lillys strategy for tirzepatide (Mounjaro and Zepbound) is defined by clinical differentiation and an aggressive manufacturing moat
KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)
You would be supporting a local institution, founded upon principles of integrity and strong editorial standards
Genetic context alone does not determine whether special issuance will be approved
Food and Drug Administration has recorded 209 incidents of Wegovy patients suffering from gastrointestinal disorders this year, 42 of whom were hospitalized
As cells composed of high levels of mitochondria, RGCs maintain a balanced microenvironment via the tight regulation of mitochondria integrity through the process of mitophagya PINK/Parkin-dependent pathway
